We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Antibody–Drug Conjugates: A Novel Paradigm for Cancer Therapy

Drug Conjugates
Credit: iStock

Chemotherapy is one of the most widely used treatment approaches for cancer. However, it can often cause serious side effects, posing challenges for drug developers.

Antibody–drug conjugates (ADCs) combine the effective killing power of small molecule cytotoxins and the highly specific targeting ability of monoclonal antibodies, and so can precisely deliver cytotoxins to tumor cells, while minimally affecting normal cells.

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

Download this whitepaper to learn more about:

  • Currently approved ADCs and their indications
  • The mechanism of action of ADC drugs
  • Overcoming cytotoxic payload challenges in drug development

Access this Whitepaper for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.